Overview
OutSee is a Cambridge-based genomics and drug discovery company that uses AI-driven predictive genomics to identify therapeutic targets. The company leverages its proprietary Nomaly platform to generate data-backed target candidates for pharmaceutical development. OutSee partners with preclinical contract research organizations to advance lead drug candidates through early-stage discovery programs.
Frequently asked questions
- What is OutSee's core technology platform?
- OutSee's Nomaly platform is a next-generation genomic analysis tool that uses AI-based predictive genomics to identify and validate therapeutic targets. The platform harnesses powerful data-driven insights to transform the drug discovery process by enabling companies to identify targets with strong scientific backing before entering preclinical development.
- What funding and partnerships does OutSee have?
- OutSee closed a £2.5 million seed funding round in January 2026, led by Ahren Innovation Capital with participation from Kadmos Capital, Panacea, Empirical Ventures, and 26 independent angel investors. The company has established a strategic partnership with o2h discovery, a preclinical contract research organization, to advance collaborative drug discovery programs for lead target candidates.
- What services does OutSee provide to pharmaceutical companies?
- OutSee provides target discovery services using its proprietary Nomaly platform to identify therapeutic targets backed by genomic data. The company works with partners like o2h discovery to launch collaborative drug discovery programs, enabling pharmaceutical R&D teams to accelerate early-stage development with validated target candidates.
- Where is OutSee located?
- OutSee is headquartered in Cambridge, UK. The company's strategic partner o2h discovery also maintains operations in Cambridge, UK, and Ahmedabad, India, providing integrated preclinical drug discovery capabilities.
- What stage of drug development does OutSee support?
- OutSee operates at the target discovery and early preclinical stage of drug development. The company identifies therapeutic targets using genomic analysis, which are then advanced through collaborative programs with contract research organizations for lead candidate development.